Posted in Constellation in the News, Newsroom
CAMBRIDGE, MA – October 20, 2008 – Constellation Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function, today will present at the 2008 Boston Biotech R&D Conference, at 3:40 PM, October 22, 2008 at Harvard Medical School in Boston, Mass. Robert Tepper, M.D., Constellation Chief Scientific [...]
Read more »
Posted in Constellation in the News, Newsroom
Constellation Pharmaceuticals is “Fierce,” on Leading Edge of Biotech CAMBRIDGE, MA – June 24, 2008 – Constellation Pharmaceuticals announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company [...]
Read more »
Posted in Constellation in the News, Newsroom
Company Founded by Pioneers in Emerging Field of Epigenetics CAMBRIDGE, MA – April 29, 2008 – Constellation Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function, today announced that it has closed a $32 million Series A financing. Proceeds from the financing will be used to [...]
Read more »
